Trial Profile
A Phase III, Randomized, Double-Blind Study of Ceftobiprole Versus Comparator in the Treatment of Complicated Skin and Skin Structure Infections
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Apr 2016
Price :
$35
*
At a glance
- Drugs Ceftobiprole medocaril (Primary) ; Vancomycin
- Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections; Staphylococcal infections
- Focus Registrational; Therapeutic Use
- Acronyms STRAUSS-I
- Sponsors Basilea Pharmaceutica; Janssen Research & Development
Most Recent Events
- 15 Apr 2016 According to a Basilea Pharmaceutica media release, results of pooled post hoc analysis from four phase III studies four double-blind, randomized, phase 3 studies in complicated skin or pulmonary infections were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
- 12 Apr 2016 Results (post-hoc pooled analysis of this and other three studies, n = 3031) assessing clinical cure and mortality presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases.
- 31 Dec 2009 The US FDA stated that the NDA could not be approved based on inadequate monitoring of the STRAUSS I and II clinical trial sites, and the high proportion of unreliable/unverifiable trial data, according to a Basilea media release.